Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 9.3% – Time to Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) fell 9.3% during trading on Monday . The stock traded as low as $0.25 and last traded at $0.25. 26,384,189 shares were traded during trading, a decline of 60% from the average session volume of 66,618,578 shares. The stock had previously closed at $0.28.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on Tonix Pharmaceuticals in a research report on Thursday, January 9th. They issued a “hold” rating for the company.

Tonix Pharmaceuticals Stock Down 4.0 %

The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The company has a 50-day simple moving average of $0.25 and a two-hundred day simple moving average of $0.31. The stock has a market cap of $40.74 million, a P/E ratio of 0.00 and a beta of 2.02.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. The company had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. On average, equities analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.